NEW YORK (GenomeWeb) – CareDx said after the close of the market on Tuesday that its first quarter revenues grew 22 percent year over year. 

For the three months ended March 31, the Brisbane, California-based molecular diagnostics firm posted $7.2 million in revenues, up from $5.9 million in Q1 2014, and beating the consensus Wall Street estimate of $6.8 million.